RetinalGenix’s Selling Stockholders to Sell Resale Shares of Common Stock at $1 Per Share as they Promote Two UV Devices to Prevent Blindness

RetinalGenix delivered its Prospectus to the U.S. Securities and Exchange Commission filed on October 8, 2021. This prospectus relates to the sale by the selling stockholders named in this prospectus of RetinalGenix Technologies Inc. of 1,591,806 shares of common stock, par value $0.0001 per share, including 1,389,906 outstanding shares of common stock, 182,000 shares of…